Stay updated with breaking news from Contract Pharmacies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Last week, we hosted an informative webinar on the 340B program and how it has changed drastically with the growing list of drug manufacturers restricting access to medications provided by some contract pharmacies. In this webinar, we talked about what is happening, how to identify the impact on your particular 340B program, and how to develop a plan to move forward. Here’s a replay of 340B for Contract Pharmacies – The Good, Bad, and Downright Ugly.
On Tuesday, we hosted an informative webinar on the 340B program and how it has changed drastically with the growing list of drug manufacturers restricting access to medications provided by some contract pharmacies. In this webinar, we talked about what is happening, how to identify the impact on your particular 340B program, and how to develop a plan to move forward. Here’s a replay of 340B for Contract Pharmacies – The Good, Bad, and Downright Ugly.
The 340B program has changed drastically with the growing list of drug manufacturers restricting access to medications provided by some contract pharmacies. Now, more than ever, it is essential to understand what is happening, identify the impact on your particular 340B program, and develop a plan moving forward. That’s why we’re offering a webinar designed to tell you what you need to know. Register now for 340B for Contract Pharmacies – The Good, Bad, and Downright Ugly, at 2 p.m. ET on Tuesday.
To embed, copy and paste the code into your website or blog: On May 17, 2021, the Biden Administration took its first major action impacting the 340B Drug Discount Program. In a forceful statement, the Administration made plain its views on a major controversy that has pitted drug manufacturers against 340B covered entities for the past year - proclaiming that drug manufacturers are violating the 340B statute by restricting covered entity access to 340B discounts for drugs dispensed through 340B contract pharmacies. Background As regular readers of our blog know, for a number of years the...
Tuesday, May 18, 2021 On May 17, 2021, the Biden Administration took its first major action impacting the 340B Drug Discount Program. In a forceful statement, the Administration made plain its views on a major controversy that has pitted drug manufacturers against 340B covered entities for the past year - proclaiming that drug manufacturers are violating the 340B statute by restricting covered entity access to 340B discounts for drugs dispensed through 340B contract pharmacies. Background As regular readers of our blog know, for a number of years the 340B Program has been at a c...